PE 22-28 TREK-1 blocker, anyone following the preclinical antidepressant angle?

Posted by sleep_coastal in Research & News - 1 points, 0 comments.

Been reading up on PE 22-28, the spadin-derived peptide that blocks the TREK-1 potassium channel. The animal data on rapid antidepressant effects and neurogenesis is interesting. You can read the profile here: /peptides/pe-22-28.

What catches my attention is the mechanism. Instead of messing with serotonin reuptake directly, it blocks a background potassium channel, which enhances serotonergic signaling downstream. That is a different lever than SSRIs pull.

Anecdotally, the cognitive peptides I have tried, Semax and Adamax, felt like they did something within days rather than weeks. If PE 22-28 actually works in humans the way it does in animal models, that fast onset would line up with what I have noticed from other neuroplasticity-oriented compounds. But this is ALL preclinical.

No human safety data. No established dosing. The short half-life as a peptide is a real problem too.

You would probably need some kind of modified delivery to get meaningful exposure. I keep seeing people in biohacking circles talk about it like it is right around the corner. It is not.

The jump from mouse synaptogenesis to human mood improvement is huge and often does not survive the trip. Still, the TREK-1 target itself feels promising. Anyone else been following the TREK-1 research trail, or tried anything in this spadin family?

Community discussion - research and educational context only. Not medical advice.